BPG is committed to discovery and dissemination of knowledge
Homepage
Online Submission
Number of total visits
30622883
Number of visits today
9160
Number of downloads
13030742
MEMBERSHIP
Cited by in F6Publishing
For:
Xia S , Ji L , Tao L , Pan Y , Lin Z , Wan Z , Pan H , Zhao J , Cai L , Xu J , Cai X . TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance. Cell Mol Gastroenterol Hepatol 2021;12 :1121-43. [PMID: 33962073 DOI: 10.1016/j.jcmgh.2021.04.016 ] [ Cited by in Crossref: 1] [ Cited by in F6Publishing: 1 ] [ Article Influence: 1.0 ] [ Reference Citation Analysis ]
Number
Citing Articles
1
Jo S , Samarpita S, Lee JS, Lee YJ, Son JE, Jeong M, Kim JH, Hong S, Yoo S, Kim W, Rasool M, Byun S. 8-Shogaol Inhibits Rheumatoid Arthritis through Targeting TAK1. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106176 ] [ Reference Citation Analysis ]
2
Pietrobono S , Melisi D . A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib. Cell Mol Gastroenterol Hepatol 2021;12 :1151-2. [PMID: 34181901 DOI: 10.1016/j.jcmgh.2021.06.005 ] [ Reference Citation Analysis ]
3
Yeung CLS , Yam JWP. Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.02.013 ] [ Reference Citation Analysis ]
© 2004-2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA California Corporate Number: 3537345
